CN104212818B - Optimized gene sequence of human papillomavirus 31 type L1 protein - Google Patents
Optimized gene sequence of human papillomavirus 31 type L1 protein Download PDFInfo
- Publication number
- CN104212818B CN104212818B CN201310217596.6A CN201310217596A CN104212818B CN 104212818 B CN104212818 B CN 104212818B CN 201310217596 A CN201310217596 A CN 201310217596A CN 104212818 B CN104212818 B CN 104212818B
- Authority
- CN
- China
- Prior art keywords
- albumen
- hpv31l1
- virus
- hpv
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to the field of molecular virology and immunology, and particularly, relates to a gene sequence for encoding a human papillomavirus 31 type L1 protein and with a termination codon of TAG, and an encoded protein and a preparation method thereof, and virus-like particles containing the encoded protein; the protein and the virus-like particles can be used for preventing HPV (especially HPV31) infection and diseases such as cervical cancer and the like caused by the HPV (especially HPV31) infection. The invention also relates to an application of the protein and the virus-like particles in preparation of a pharmaceutical composition or a vaccine. The pharmaceutical composition or the vaccine is used for preventing the HPV (especially HPV31) infection and the diseases such as cervical cancer and the like caused by the HPV (especially HPV31) infection.
Description
Technical field
The present invention relates to Molecular Virology and field of immunology.In particular it relates to a kind of termination codon is TAG
Coding 31 type L1 albumen of human papillomavirus gene order, its coding albumen and preparation method, and comprising its encode
Albumen virus-like particle（Virus-Like Particle, VLP）, the albumen and virus-like particle can be used to prevent HPV
（Particularly HPV31）Infect and by HPV（Particularly HPV31）Disease such as cervical cancer etc. caused by infection institute.The present invention is also related to
And above-mentioned albumen and virus-like particle are used to prepare the purposes of pharmaceutical composition or vaccine, described pharmaceutical composition or vaccine are used for
Prevention HPV（Particularly HPV31）Infect and by HPV（Particularly HPV31）Disease such as cervical cancer etc. caused by infection institute.
Background technology
Human papillomavirus (Human Papillomavirus, HPV) are one kind without peplos DNA viruses.Its virion
A diameter of 45～55nm, viral capsid are symmetrical in 20 face bodies, have 72 shell microgranules, by the Major capsid protein L1 of virus and secondary
Capsid protein L2 is constituted.
The HPV being currently known there are about more than 90 kinds of hypotype, mainly cause skin in crowd, mucosa it is all kinds of benign and pernicious
Pathological changes.HPV Molecule Epidemiology Investigation confirms that high-risk HPV infection is the important startup factor of cervix uteri carcinogenesis.In all palaces
In neck cancer specimen, HPV DNA recall rates up to more than 80%.Cervical cancer is a kind of common female malignant, its sickness rate
Breast carcinoma is only second to, the health of women is seriously threaten.According to statistics, the neopathy of 490,000 is there are about in annual world wide
Example, there are about 270,000 people and dies from the disease（Boyle, P., and J.Ferlay.Ann Oncol2005,16:481-8）.Institute
In having cases of cervical cancer, betide developing country account for about 83%, and in these countries, cervical cancer even can account for female
The 15% of property malignant tumor.Areas to the south of the Sahara, Central and South Asia, Latin America, East Asia are the district occurred frequently of cervical cancer.China
Fall within cervix uteri high cancer incidence area.In Lueyang, Shaanxi Province county, in married woman, the sickness rate of cervical cancer is up to 1026/100000.
Find about the meta-analysises of HPV types distribution in cervical cancer specimen in world wide, it is modal in cervical cancer
In the high-risk type of 15 kinds of HPV, HPV31 after HPV16, HPV18, HPV58, HPV33, HPV45, positioned at the 6th；And in palace
Neck cancer Africa south occurred frequently and Central America area, HPV31 even occupy the 3rd of the HPV types for causing cervical cancer
（Clifford GM, Smith JS, Plummer M, et a1.Br J Cancer, 2003,88 (1)：63-73）.This explanation
Infection rate in HPV31 woman uterus cancer patients worldwide is higher, is one of universal susceptible HPV types.
The HPV vaccines for having listed at present are Merck'sAnd GSK, above two
Vaccine contains HPV6/11/16/18 and HPV16/18VLP respectively, but is not included in China and Asia women universal susceptible
HPV31 type VLP, cannot also provide the infection and pathogenic offer protection for HPV31 types.
Therefore, for China and the developing country women such as Asia safely and effectively HPV vaccines, especially for
The vaccine of the high-risk type such as HPV16,18 and 31, is effectively to prevent cervical cancer, improves numerous women（Particularly China and Asia woman
Female）The effective way of health status.
HPV L1 albumen is major capsid protein, and molecular weight is 55-60kDa, is HPV vaccine main candidate immunizing antigens.
The HPV L1 albumen expressed in various expression systems without the need for L2 albumen auxiliary may be formed on morphosiss with natural viral
The similar virus-like particle of granule.The virus-like particle is icosahedron cubic symmetry structure, by the pentamer of 72 L1 albumen
Composition.Which remains the natural epitopes of virion, with stronger immunogenicity, can induce in homotype HPV virus
With antibody (Kirnbauer, R., F.Booy, et al.1992Proc Natl Acad Sci U S A89 (24):12180-4).
Also, virus-like particle is without viral nucleic acid, without potential carcinogenic danger, with good safety.Therefore, VLP vaccines have been
Become the Main way of HPV Vaccine Developments.
The key of HPV VLP vaccine developments is can efficiently to prepare highly purified VLP samples in a large number.More commonly use at present
VLP expression systems can be divided into eukaryotic expression system and prokaryotic expression system.
Conventional eukaryotic expression system has pox viruses express system, insect baculovirus expression system, yeast expression system.
In eukaryotic expression system, the destruction of expressed HPV L1 albumen native conformation is few, can spontaneously form VLP, often need to only carry out letter
Single density gradient centrifugation is obtained the VLP of purification, provides great convenience for purification work.But due to eukaryotic expression system
The expression of system is low, and toxigenic capacity is high, brings extreme difficulties to large-scale industrial production.The HPV vaccines for having listed at presentSaccharomyces Serevisiae Expression System is employed, its expression is low, production cost is high, therefore the product price is higher,
Affect its extensive application.
Had been reported using escherichia expression system expression HPVL1 albumen in prokaryotic expression system.For example report
Using escherichia coli expression HPV16L1 albumen（Banks, L., G.Matlashewski, et al. (1987) .J Gen
Virol68(Pt12):3081-9）.But the HPV L1 albumen of escherichia coli expression loses its native conformation mostly, it is impossible to produce
For the protection antibody of HPV.Although or above-mentioned albumen is also obtained HPV VLP by steps such as occlusion body purification, renaturation
（Kelsall, S.R.and J.K.Kulski (1995) .J Virol Methods53 (1):75-90）But, in renaturation process
Middle loss of proteins amount is big, and yield is low, accordingly, it is difficult to apply in large-scale production.Although HPV L1 albumen can also be in large intestine
Expressed with correct conformation solubility in bacillus, be dissolved in the cracking supernatant of thalline, but its expression is relatively low, and supernatant
Middle foreign protein species is more and measures greatly, will therefrom be purified into destination protein difficulty quite big.Although also there is document report to melt by GST
The mode for closing expression can increase the expression of L1 albumen in supernatant, and help the purification of destination protein（Li, M.,
T.P.Cripe, et al. (1997) .J Virol71 (4):2988-95）, but the cutting of fusion protein generally require it is expensive
Enzyme, cannot still be applied to large-scale production.
Therefore, this area still needs and inexpensive can obtain and can induce the protection antibody for HPV31
HPV31L1 albumen and the virus-like particle being made from it, so that large-scale industrial production vaccine for cervical cancer is possibly realized.
Additionally, intracellular protein synthesis research finds, the translation of nascent protein peptide chain is completed with release mainly by two
Class peptide chain release factor (polypeptide release factor, RF) is completing.Wherein, first kind releasing factor is password
Sub- atopen, Equations of The Second Kind releasing factor are the nonspecific factor of codon, are that one kind depends on first kind peptide chain to discharge
The factor and ribosomal GTP enzymes, promote the biologic activity of first kind releasing factor. this two classes factor synergism, it is common complete
Into the terminating reaction of protein synthesis（Zhu Yuxian, Li Yizhu. modern molecular biology, second edition. Beijing:Higher education publishing
Society., 2002,119-129）.Wherein, the effect of first kind RFs is more crucial, identification termination signal, promotion peptide acyl-tRNA ester bonds
Hydrolysis, prevent protein translation during mistake read over, finally discharge correct protein.In prokaryote first
Class RFs is RF1/RF2, RF1 identification UAG/UAA, RF2 identification UGA/UAA.It is eRFl in eukaryote, can recognizes that 3 terminations are close
Numeral.Although in prokaryote, UAA can be recognized by RF1 and RF2, and UAG and UGA are only recognized by one of which RF, its end
Only efficiency but has difference, (Wang Y H, Zhang CT, Dong P related to the series of factors such as the sequence before termination codon
X.Biopolymers,2002,63:207-216)。
The content of the invention
The present invention is at least partially based on having now surprisingly been found that for inventor：Can big scale using escherichia expression system
It is the HPV31L1 genes of TAG up to termination codon, obtains the HPV31L1 albumen that can induce the neutralizing antibody for HPV31,
With other two kinds of termination codoies（TGA and TAA）Gene compare, the gene can greatly improve the efficiency of translation termination, it is to avoid
The generation of the HPV31L1 albumen of error ending, reduces the difficulty of purifying process, and in making stock solution, purity of protein is improved from 85%
To 95% or higher, and the albumen Jing after purification is further assembled to process and can be obtained the inducible protection for HPV31
The virus-like particle of property antibody, packaging efficiency also reach more than 95%, are higher by remaining 2 kinds of termination codon encoding proteins about 10%.
Therefore, in one aspect, the present invention relates to a kind of termination codon is the gene of the coding HPV31L1 albumen of TAG,
, compared with the gene of encoding wild type HPV31L1 albumen, termination codon is TAG rather than TAA or TGA for which.
In yet another aspect, the present invention relates to termination codon for TAG coding HPV31L1 albumen polynucleotide and
Carrier containing the polynucleotide.
The carrier that can be used to insert polynucleotide of interest is it is known in the art that including but not limited to cloning vehicle and table
Up to carrier.In one embodiment, carrier is such as plasmid, cosmid, phage, coemid etc..
In yet another aspect, the invention further relates to include the host cell of above-mentioned polynucleotide or carrier.Such host is thin
Born of the same parents include but is not limited to, prokaryotic cell such as Bacillus coli cells, and eukaryotic cell such as yeast cells, insect cell, plant
Thing cell and zooblast（Such as mammalian cell, such as mouse cell, people's cell etc.）.The host cell of the present invention can be with
It is cell line, such as 293T cells.
In yet another aspect, the present invention relates to a kind of HPV31L1 virus-like particles, the wherein virus-like particle contain this
HPV31L1 albumen coded by bright nucleotide sequence or its variant, or by the coding HPV31L1 albumen or its variant group of the present invention
Into or formed.
In yet another aspect, the invention further relates to include above-mentioned HPV31L1 albumen or its variant, or above-mentioned polynucleotide or
The compositionss of carrier or host cell or HPV31 virus-like particles.In a preferred embodiment, the compositionss are included
The encoding proteins or its variant of the present invention.In another preferred embodiment, HPV31 of the compositionss comprising the present invention
Virus-like particle.
In yet another aspect, the invention further relates to a kind of pharmaceutical composition or vaccine, it is viral which includes HPV31 of the invention
Sample granule, optionally also includes pharmaceutically acceptable carrier and/or excipient.The pharmaceutical composition or vaccine of the present invention can be used
In prevention HPV（Particularly HPV31）Infect or by HPV（Particularly HPV31）Disease such as cervical cancer etc. caused by infection institute.
In a preferred embodiment, the HPV31 virus-like particles are preventing HPV infection or cervical cancer effective dose
Exist.In another preferred embodiment, pharmaceutical composition of the invention or vaccine are also selected from following comprising at least one
Virus-like particle：HPV6L1 prion sample granules, HPV11L1 prion sample granules, HPV16L1 prion samples
Grain, HPV18L1 prion sample granules, HPV45L1 prion sample granules, HPV33L1 prion sample granules, HPV52L1
Prion sample granule, humanpapilloma virus 58 L1 protein virus-like particle；Preferably, these virus-like particles are independently of one another preventing palace
Neck cancer or corresponding HPV Subtypes effective dose are present.
The pharmaceutical composition or vaccine of the present invention can be administered by means commonly known in the art, such as but not limited to be led to
Cross oral or injection to be administered.In the present invention, particularly preferred method of application is injection.
In a preferred embodiment, pharmaceutical composition or vaccine of the invention are applied in a unit
With.For example but it is not intended to limit the present invention, the amount of the HPV31 virus-like particles included in per unit dose is 5 μ g-80 μ g, excellent
Select 20 μ g-40 μ g.
In yet another aspect, the present invention relates to a kind of side for obtaining the HPV31L1 albumen coded by gene order of the present invention
Method, which includes using the HPV31L1 albumen coded by escherichia expression system expression gene order of the present invention, then will contain
The cracking supernatant of the albumen carries out purification process.
In a preferred embodiment, the method for obtaining the HPV31L1 albumen coded by the present invention includes
A) in HPV31L1 albumen described in expression in escherichia coli,
B) escherichia coli for expressing the HPV31L1 albumen are crushed in solution of the salinity for 100mM-600mM, point
From obtaining supernatant,
C) with water or low salt solutions by b）The salinity of the supernatant of acquisition is down to 100mM or following, and most as little as 0, and receive
Collection precipitation,
D) by c）Obtain be deposited in 150mM-2500mM saline solution in dissolve again, while add reducing agent, separate
To solution, the HPV31L1 albumen containing purity at least 50% in the solution.
More generally, the invention further relates to a kind of side of acquisition HPV L1 albumen HPV31L1 albumen for example of the invention
Method, which includes
A) the HPV L1 genes of HPV L1 albumen are encoded in expression in escherichia coli,
B) escherichia coli of expression HPV L1 albumen are crushed in solution of the salinity for 100mM-600mM, is separated
To supernatant,
C) with water or low salt solutions by b）The salinity of the supernatant of acquisition is down to 100mM or following, and most as little as 0, collect
Precipitation,
D) by c）Obtain be deposited in 150mM-2500mM saline solution in dissolve again, while add reducing agent, separate
To solution, the HPV L1 albumen containing purity at least 50% in the solution.
The invention further relates to a kind of method of the HPV31 virus-like particles for obtaining the present invention, which is obtaining present invention acquisition
HPV31L1 albumen on the basis of, including step：
E) by the above-mentioned HPV31L1 albumen of purity at least 50% further by chromatographic purification,
F) the HPV31L1 albumen obtained in step e) is removed into reducing agent.
The invention further relates to a kind of method for preparing vaccine, which is included the HPV31 virus-like particles and pharmacy of the present invention
Acceptable carrier and/or excipient mixing, optionally also mix one or more be selected from HPV6,11,16,18,45,33,52
With the virus-like particle of 58 HPV types.As discussed above, the vaccine for being obtained can be used for preventing HPV（Particularly
HPV31）Infect or by HPV（Particularly HPV31）Disease such as cervical cancer etc. caused by infection institute.
In yet another aspect, the present invention relates to a kind of prevention HPV infection or the method by the caused disease of HPV infection institute,
Which is included the HPV31 virus-like particles of the invention or pharmaceutical composition or vaccine administration of prevention effective dose to tested
Person.In a preferred embodiment, the HPV infection is HPV31 infection.In another preferred embodiment, institute
State and included but is not limited to by disease caused by HPV infection institute, cervical cancer.In another preferred embodiment, it is described tested
Person is mammal, for example people.
In yet another aspect, the HPV31L1 albumen or HPV31 virus-like particles according to coded by the present invention is further related in system
Purposes in standby pharmaceutical composition or vaccine, described pharmaceutical composition or vaccine are used to prevent HPV infection or by HPV infection institute
Caused disease.In a preferred embodiment, the HPV infection is HPV31 infection.In another preferred embodiment party
In case, caused by the institute by HPV infection, disease is included but is not limited to, cervical cancer.
The explanation and explanation of relational language in the present invention
In the present invention, unless otherwise stated, Science and Technology noun used herein has art technology
The implication are generally understood that by personnel.Also, cell culture used herein, molecular genetics, nucleic acid chemistry, immunological experiment
Room operating procedure is widely used conventional steps in corresponding field.Meanwhile, for a better understanding of the present invention, it is provided below
The definition and explanation of relational language.
According to the present invention, term " variant " refers to such albumen, the HPV31L1 that its aminoacid sequence is encoded with the present invention
Albumen（Such as SEQ ID NO：Albumen shown in 4）Aminoacid sequence have one or more（Such as 1-10 or 1-5 or 1-
3）Aminoacid is different or has at least 60%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homogeneity, and
Which remains the necessary characteristic of the albumen.Term " necessary characteristic " can be one or more in following characteristic herein：
The neutralizing antibody for HPV31 can be induced；Can express to solubility in escherichia coli；Using table involved in the present invention
The purifying protein of high yield is obtained in that up to purification process.Term " homogeneity " is the phase to nucleotide sequence or aminoacid sequence
Like measuring for property.Generally series arrangement is got up, to be matched to greatest extent." homogeneity " itself has known in this field
Meaning and available disclosed algorithm（Such as BLAST）To calculate.
According to the present invention, term " escherichia expression system " refers to the expression being made up of escherichia coli (bacterial strain) and carrier
System, wherein escherichia coli（Bacterial strain）From bacterial strain available on the market, such as but not limited to：ER2566, BL21
(DE3), B834 (DE3), BLR (DE3).
According to the present invention, term " carrier（vector）" refer to, a kind of nucleic acid delivery that polynucleotide can be inserted
Instrument.When the albumen coded by carrier can make the polynucleotide of insertion obtains expression, carrier is referred to as expression vector.Carrier can be with
By conversion, transduction or transfection importing host cell so as to which the hereditary material element of carrying obtains table in host cell
Reach.Carrier be well known to a person skilled in the art, including but not limited to：Plasmid；Phage；Coemid etc..
According to the present invention, term " HPV31L1 albumen " refers to that, in wild type HPV31L1 albumen, its example includes but do not limit
P17388.1, AEI61965.1, AEI61021.1, AEI61005.1, AEI61949.1 in ncbi database,
AEI61894.1, AEI61077.1, AEI61013.1, AEI61989.1, AEI61957.1, AEI61053.1, AEI61093.1,
AEI61069.1, AEI61981.1 wait total length L1 albumen.
Term " HPV31L1 protein gene fragment of the termination codon for XXX " refers to that termination codon is XXX（Can be
Any one of TAA, TAG or TGA）Encoding wild type HPV31L1 gene order, wherein wild type HPV31L1 albumen base
The sequence of cause is such as, but not limited to following sequence in ncbi database：J04353.1, HQ537671.1, HQ537678.1,
HQ537676.1, HQ537669.1, U37410.1, HQ537685.1, HQ537677.1, HQ537674.1, HQ537670.1,
HQ537682.1, HQ537687.1, HQ537684.1, HQ537673.1 etc..The invention provides coding human papillomavirus 31
The detached nucleic acid of type L1 albumen, it is characterised in that termination codon is TAG；Preferably, the nucleotide sequence pin of the nucleic acid
Expression in escherichia coli is optimized；It is highly preferred that the nucleotide sequence of the nucleic acid such as SEQ ID NO:Shown in 1.
According to the present invention, term " pharmaceutically acceptable carrier and/or excipient " is referred in pharmacology and/or physiologically
The carrier compatible with experimenter and active component and/or excipient, which is well known in the art（See, for example, Remington's
Pharmaceutical Sciences.Edited by Gennaro AR,19th ed.Pennsylvania:Mack
Publishing Company,1995）, and including but not limited to：PH adjusting agent, surfactant, adjuvant, ionic strength increase
Strong agent.For example, pH adjusting agent includes but is not limited to phosphate buffer；Surfactant includes but is not limited to cation, it is cloudy from
Son or nonionic surfactant, such as Tween-80；Adjuvant includes but is not limited to aluminium adjuvant（Such as aluminium hydroxide）, not
Family name's adjuvant（Such as complete Freund's adjuvant）；Ionic strength reinforcing agent includes but is not limited to Sodium Chloride.
According to the present invention, term " effective dose " is the amount for referring to effectively realize expected purpose.For example, prevention disease（Example
Such as HPV infection）Effective dose is referred to, effectively can be prevented, prevents, or postpones disease（Such as HPV infection）Generation amount.Determine
Such effective dose is within the limit of power of those skilled in the art.
According to the present invention, term " chromatography " is including but not limited to：Ion exchange chromatography（Such as cation exchange color
Spectrum）, hydrophobic interaction chromatograph, adsorption chromatography（Such as hydroxylapatite chromatography）, gel filtration（Gel exclusion）Chromatography, parent
And chromatography.
According to the present invention, the HPV31L1 albumen of the HPV31L1 sequential codings with TAG as termination codon of the present invention is excellent
Choosing is obtained as follows：By expression HPV31L1 albumen escherichia coli salinity be 100-600mM, preferred 200-
Crushed in the buffer of 500mM, centrifugal breaking solution obtains supernatant；With water or low salt concn（Usually less than crush and use
Salinity）Solution reduce gained supernatant salinity to salinity 100mM-0mM, so as to HPV31L1 albumen is in supernatant
Precipitate in liquid；It is 150-2500mM that will be deposited in containing reducing agent and salinity, is dissolved in the solution of preferred more than 200mM again,
So as to the isolated solution containing HPV31L1 albumen, wherein the purity of the albumen is at least 50%, preferably at least 70%, more
Preferably at least 80%.
Can be used for the buffer in the method for the present invention is it is known in the art that including but is not limited to, Tris buffer, phosphorus
Phthalate buffer, HEPES buffer solution, MOPS buffer etc..
According to the present invention, the broken of host cell can be realized by various methods well known to those skilled in the art, be wrapped
Include but be not limited to broken homogenizer, homogenizing crusher machine, ultrasonic Treatment, grinding, high-pressure extrusion, bacteriolyze ferment treatment etc..
Can be used for the salt in the method for the present invention and include but is not limited to acid salt, basic salt, such as neutral salt, alkali metal
Salt, alkali salt, ammonium salt, hydrochlorate, sulfate, bicarbonate, phosphate or hydrophosphate, particularly NaCl, KCl,
NH4Cl、(NH4)2SO4In one or more.Particularly preferred salt is NaCl.Can be used for the reducing agent in the method for the present invention
Including but not limited to DTT, 2 mercapto ethanol, its consumption include but is not limited to 10mM-100mM.
HPV31 virus-like particles of the invention can be obtained as follows：By above-mentioned purity at least 50%
HPV31L1 albumen is further separated for example, by chromatography, obtains purified HPV31L1 protein solutions；Removing should
Reducing agent in solution, obtains the HPV31 virus-like particles.Remove reducing agent mode be it is known in the art, including but
It is not limited to, dialyses, ultrafiltration or chromatography etc..
The beneficial effect of the invention
Eukaryotic expression system and prokaryotic expression system can be divided into currently used for the expression system for preparing HPV virus-like particles
System.
The HPV L1 albumen native conformation destruction expressed in eukaryotic expression system is few, can spontaneously form VLP, often only need
The VLP with correct conformation is obtained by carrying out simple purge process.But current eukaryotic expression system such as baculoviruss table
Have up to system and yeast expression system that expression is low, the defect such as toxigenic capacity height brings pole to large-scale industrial production
It is big difficult.
In prokaryotic expression system, escherichia expression system has toxigenic capacity low, the big advantage of expression.However,
Correct native conformation is often lost in the HPV L1 albumen of expression in escherichia coli, is expressed in precipitation with occlusion body form.
Albumen to being expressed in occlusion body carries out renaturation and is still a global problem at present.Renaturation is difficult and inefficiency is caused
The VLP that correct conformation is obtained from occlusion body is difficult to implement in large-scale production, can only be confined to small-scale laboratory
In research.Although HPV L1 can also be expressed in escherichia coli with correct conformation solubility, its expression is low.And
And, it is also extremely difficult HPV L1 albumen to be purified into from the cracking supernatant of the escherichia coli comprising miscellaneous soluble protein,
Generally require by means such as amalgamation and expression and affinity chromatographs, and these means generally require costliness enzyme, therefore, still without
Method realizes industrialized production.
The present invention provide the HPV31L1 sequences with TAG as termination codon, and its coding HPV31L1 albumen and
The preparation method of albumen efficiently solves the problems referred to above.First, the present invention is using the HPV31L1 sequences that TAG is termination codon
Row are expressed, and compared with sequence of the termination codon for TAA or TGA, greatly improve the efficiency of translation termination, it is to avoid mistake
The generation of the HPV31L1 albumen of termination, reduces the difficulty of purifying process, and in making stock solution, purity of protein brings up to 95% from 85%,
The efficiency of assembling virus-like particle brings up to 98% from 90%.Secondly, HPV31L1 eggs are expressed using escherichia expression system
In vain, it is ensured that its high expression.Again, the present invention is using the egg in gentle means selective precipitation escherichia coli cracking supernatant
In vain, then using containing salt buffer again soluble protein, so as to make purity of protein on the premise of the correct conformation of albumen is kept
It is obviously improved, and the protein solution for obtaining can directly passes through chromatography such as ion-exchange chromatography and hydrophobic exchange
Chromatography is further purified, and obtains highly purified destination protein（For example purity reaches 95%）.Further, what is obtained is high-purity
Degree albumen can be assembled into virus-like particle, and the virus-like particle can in vivo induced high titers for HPV31's
Neutralizing antibody, with good immunogenicity, is a kind of good vaccine form, can be used to prevent infection of the HPV31 to human body.
As can be seen here, the present invention has advantages below：The albumen of the present invention can realize a large amount of correct tables in escherichia expression system
Reach；Preparation method of the present invention is without using expensive enzyme, with low cost；HPV31L1 albumen structure in purge process
Through violent degeneration renaturation process, lose little as not, yield is high；The virus-like particle formed by HPV31L1 albumen can
The protection antibody for HPV of induced high titers, can be used to produce vaccine.Therefore, the present invention coded by HPV31 albumen and
Its preparation method can be applicable to large-scale industrial production, and be possibly realized large-scale industrial production vaccine for cervical cancer.
Embodiment of the present invention is described in detail below in conjunction with drawings and Examples, but people in the art
Member will be understood that drawings below and embodiment are merely to illustrate the present invention, rather than the restriction to the scope of the present invention.With reference to the accompanying drawings
With the following detailed description of preferred embodiment, the various purposes of the present invention and favorably aspect are to those skilled in the art
Will be apparent from.
Description of the drawings
Fig. 1 shows that the sds polyacrylamide of the HPV31Ctag-L1 albumen obtained in the different step of embodiment 2 coagulates
The result of gel electrophoresis.Swimming lane 1：Bacteria break supernatant（That is, the supernatant of acquisition is centrifuged after crushing thalline）；Swimming lane 2：SP
Sepharose4Fast Flow post 1000mmol/LNaCl elutriated fractions；Swimming lane 3：Butyl Sepharose4Fast Flow posts
300mmol/LNaCl elutriated fractions；Swimming lane 4：CHTII post 1000mmol/LNaCl elutriated fractions.As a result show, HPV31Ctag-
After by the chromatographic step of 3 steps, purity has brought up to about 95% from about 10% before to L1 albumen（Referring to swimming lane 1 and 4）.
The HPV31Ctag-L1 albumen that Fig. 2 is obtained in showing the different step of embodiment 2, HPV31Ctaa-L1 albumen and
The result of the sds polyacrylamide gel electrophoresis of HPV31Ctga-L1 albumen.Swimming lane M：Protein markers；Swimming lane 1：
HPV31Ctaa-L1 albumen bacteria break supernatants；Swimming lane 2：HPV31Ctaa-L1SP Sepharose4Fast Flow post 1000mmol/
LNaCl elutriated fractions；Swimming lane 3：HPV31Ctaa-L1CHTII post 1000mmol/LNaCl elutriated fractions；Swimming lane 4：
HPV31Ctga-L1 albumen bacteria break supernatants；Swimming lane 5：HPV31Ctga-L1SP Sepharose4Fast Flow post 1000mmol/
LNaCl elutriated fractions；Swimming lane 6：HPV31Ctga-L1CHTII post 1000mmol/LNaCl elutriated fractions；Swimming lane 7：
HPV31Ctag-L1 albumen bacteria break supernatants；Swimming lane 8：HPV31Ctag-L1SP Sepharose4Fast Flow post 1000mmol/
LNaCl elutriated fractions；Swimming lane 9：HPV31Ctag-L1CHTII post 1000mmol/LNaCl elutriated fractions.As a result show,
After by the chromatographic step of 3 steps, purity has brought up to about 95% from about 10% before to HPV31Ctag-L1 albumen, and
After purification, purity can only bring up to 85% to HPV31Ctaa-L1 and HPV31Ctga-L1 albumen Jing same step.About 55kD's
Above purpose band, the foreign protein band for having a 60kD have impact on the purity of albumen, account for the 10% of total protein concentration.
Fig. 3 shows the electrophoresis of the HPV31Ctaa-L1 albumen after purification of gained in embodiment 2 and uses HPV31L1 special
The result of different monoclonal antibody immunoblotting.M：Protein markers；Swimming lane 1：The SDS-PAGE analysis knots of HPV31Ctaa-L1 albumen
Really；Swimming lane 2：Result of the HPV31Ctaa-L1 albumen using the special monoclonal antibody 8G6 immunoblottings of HPV31L1；Swimming lane 3：
Result of the HPV31Ctaa-L1 albumen using the special monoclonal antibody 11D2 immunoblottings of HPV31L1.As a result show, the purpose bar of about 55kD
The foreign protein band of band and 60kD can be with the special monoclonal antibody reactions of HPV31L1.
Fig. 4 shows the foreign protein band of the 60kD in embodiment 2 in the HPV31Ctaa-L1 albumen after purification of gained
The Search Results identified by mass spectrometry method.As a result show, the very big probability of the albumen is HPV31L1 albumen, match molecule and reach
To 81 points（It is credible more than 60 points）.
Fig. 5 shows the foreign protein band of the 60kD in embodiment 2 in the HPV31Ctga-L1 albumen after purification of gained
The Search Results identified by mass spectrometry method.As a result show, the very big probability of the albumen is HPV31L1 albumen, match molecule and reach
To 253 points（It is credible more than 60 points）.
Fig. 6 shows the transmission electron microscope observing of the HPV31Ctag-L1 virus-like particles of gained in embodiment 4（Amplify 100,
000 times, Bar=0.1 μm）As a result.In the visual field, visible a large amount of radiuses are the virus-like particle of 25nm or so, granular size and theory
Size is consistent, and uniformity.
Fig. 7 shows the transmission electron microscope observing of the HPV31Ctaa-L1 virus-like particles of gained in embodiment 4（Amplify 100,
000 times, Bar=0.1 μm）As a result.Virus-like particle of the visible part radius for 25nm or so in the visual field, but virus-like particle shape
Shape is more irregular, and surrounding has a large amount of unassembled albumen.
Fig. 8 shows the transmission electron microscope observing of the HPV31Ctga-L1 virus-like particles of gained in embodiment 4（Amplify 100,
000 times, Bar=0.1 μm）As a result.Virus-like particle of the visible part radius for 25nm or so in the visual field, but virus-like particle shape
Shape is more irregular, and surrounding has a large amount of unassembled albumen.
Fig. 9 shows the dynamic light scattering observed result of the HPV31Ctag-L1 virus-like particles of gained in embodiment 4.Knot
Fruit shows, the hydrated molecule kinetics radius of HPV31Ctag-L1 virus-like particles are 28.49nm, and granule assembling percentage ratio is
98.5%。
Figure 10 shows the dynamic light scattering observed result of the HPV31Ctaa-L1 virus-like particles of gained in embodiment 4.
As a result show, the hydrated molecule kinetics radius of HPV31Ctaa-L1 virus-like particles are 55.81nm, granule assembling percentage ratio is
82.9%, while also there is the component of 2.26nm, account for 10%.
Figure 11 shows the dynamic light scattering observed result of the HPV31Ctga-L1 virus-like particles of gained in embodiment 4.
As a result show, the hydrated molecule kinetics radius of HPV31Ctga-L1 virus-like particles are 52.20nm, granule assembling percentage ratio is
91.3%, while also there is the component of 10nm and 1000nm or so, the two about accounts for 10% altogether.
Figure 12 shows the HPV31L1 virus-like particles of the different termination codon gene codes of gained in embodiment 4
The result of sieve chromatography detection.As a result show, tri- kinds of HPV31Ctag-L1, HPV31Ctaa-L1 and HPV31Ctga-L1 is viral
The main peak retention time of sample granule is all 13min or so, wherein, HPV31Ctag-L1 virus-like particle peak types are the most symmetrical, nothing
Other components；HPV31Ctaa-L1 virus-like particles have 1 impurity peaks in 18min or so, it may be possible to unassembled into virus-like particle
Component, account for 10%；And HPV31Ctga-L1 virus-like particles also have 1 impurity peaks in 18min or so, while before main peak about
11min or so also has an acromion, and main peak proportion is 85% or so.
Figure 13 is shown in embodiment 6 with containing different time sections after HPV31Ctag-L1 virus-like particle Mice Inoculateds
The NAT of serum.After initial immunity 2 weeks, NAT has substantially rising；Through once strengthening exempting from
After epidemic disease, the titre of neutralizing antibody can reach 105ED50Higher level, and under having no significantly in 5 time-of-weeks in 6-11 weeks
Drop.
Figure 14 is inoculated with different phase serum after rabbit with containing HPV31Ctag-L1 virus-like particles in showing embodiment 6
NAT.After initial immunity 1 week, NAT has substantially rising；After a booster immunization, in
10 can be reached with the titre of antibody6Higher level, and in 7 time-of-weeks in 8-15 weeks have no and be remarkably decreased.
Figure 15 is using Mega4.0 softwares to 3 ' of 32 HPV31L1 in the existing NCBI nucleic acid databases gene sequences held
Arrange the result that compares.As a result show, the HPV31L1's of wild type HPV31L1 gene orders and existing synthetic
Gene order is using TAA as termination codon.
Specific embodiment
It is intended to illustrate the present invention referring now to following（And the non-limiting present invention）Embodiment describing the present invention.
Unless specifically stated otherwise, the experimental methods of molecular biology and immunodetection used in the present invention, substantially joins
According to J.Sambrook et al., molecular cloning：Laboratory manual, second edition, CSH Press, 1989, and
F.M.Ausubel et al., fine works molecular biology experiment guide, the 3rd edition, institute in John Wiley ＆ Sons, Inc., 1995
The method stated is carried out；The condition that the use of restricted enzyme is recommended according to goods producer.Those skilled in the art know, real
Apply example and describe the present invention by way of example, and be not intended to limit scope of the present invention.
The structure of the expression plasmid of the coding HPV31L1 genes of 1. different termination codoies of embodiment
It is used as the preparation of the total length HPV31L1 genetic fragment of template
The total length HPV31L1 genetic fragment of template is used as according to being synthesized by Shanghai Bo Ya companies.Synthesized gene foundation
In NCBI GenBank data bases, the coded sequence of the HPV31L1 of Serial No. J04353.1, inclined according to e. coli codon
Preferendum is optimized, and fragment total length is 1515bp, and termination codon is TAA（It is SEQ ID NO.2 in this manual）.Here
On the basis of the total length HPV31L1 genetic fragment of synthetic presses HPV31, many of coding coding HPV31L1 of the invention are prepared
Nucleotide sequence.
The structure of the nonfusion expression vector of the coding HPV31L1 genes of different termination codoies
With previous step obtain the HPV31L1 full-length gene fragments with TAA as termination codon as template, with
HPV31NF:5’-CATATgAgCCTgTggAggCCCAg-3’（SEQ ID NO：5）For forward primer（Its 5' end introduces restricted
Restriction endonuclease NdeI site CATATG, ATG are the start codon in E. coli system）；With HPV31CtagR:5'-gTCgACCTACTTCTTggTCTTCTTC-3'（SEQ ID NO：6）For reverse primer（Its 5' end introduces restricted enzyme
SalI sites）, in PCR thermal cyclers（Biometra T3）According to following condition enter performing PCR reaction.
Amplification obtains the special DNA fragmentation of size of 1.5kb or so.By the PCR primer and pMD18-T carriers commercially
（TAKARA companies produce）Connection, proceeds to escherichia coli；Plasmid is extracted, the identification of Jing NdeI/SalI enzyme action obtains inserting with TAG
For the positive colony pMD18-T-HPV31Ctag-L1 of the HPV31 genes of termination codon（Objective gene sequence is SEQ ID
NO.1）.Using same method, respectively using HPV31NF:5’-CATATgAgCCTgTggAggCCCAg-3 ' draws for forward direction
Thing, with HPV31CtaaR:5’-gTCgACTTACTTCTTggTCTTCTTC-3’（SEQ ID NO：7）For reverse primer prepare with
Positive colony pMD18-T-HPV31Ctaa-L1s of the TAA for the HPV31 genes of termination codon（Objective gene sequence is SEQ ID
NO.2）, and use HPV31NF:5’-CATATgAgCCTgTggAggCCCAg-3 ' is forward primer, with HPV31CtgaR:
5’-gTCgACTCACTTCTTggTCTTCTTC-3’（SEQ ID NO：8）Prepare with TGA as termination codon for reverse primer
The positive colony pMD18-T-HPV31Ctga-L1 of HPV31 genes（Objective gene sequence is SEQ ID NO.3）.
Using M13 (+)/(-) primer, pMD18-T-HPV31Ctag-L1 plasmids, pMD18-T- are measured respectively
The nucleotide sequence such as SEQ of the purpose fragment inserted in HPV31Ctaa-L1 plasmids and pMD18-T-HPV31Ctga-L1 plasmids
ID NO：Shown in 1-3, the aminoacid sequence of its coding is total length HPV31L1 albumen, such as SEQ ID NO：Shown in 4, but in order to
The corresponding translation product of gene of the different termination codoies of difference, is respectively designated as HPV31Ctag-L1, HPV31Ctaa-
L1 and HPV31Ctga-L1.
By above-mentioned pMD18-T-HPV31Ctag-L1 plasmids, pMD18-T-HPV31Ctaa-L1 plasmids and pMD18-T-
HPV31Ctga-L1 plasmids carry out NdeI/SalI enzyme action respectively, obtain HPV31Ctag-L1, HPV31Ctaa-L1 and
HPV31Ctga-L1 genetic fragments.Nonfusion expression vector pTO-T7 by the fragment respectively with Jing NdeI/SalI enzyme action again（Sieve
Wen Xin etc., biological engineering journal, 2000,16:53-57）It is connected, proceeds to ER2566 antibacterials；Extract plasmid, Jing NdeI/SalI
Enzyme action identification obtains positive expression the clone pTO-T7-HPV31Ctag-L1, pTO-T7-HPV31Ctaa-L1 for inserting purpose fragment
And pTO-T7-HPV31Ctga-L1.
PTO-T7-HPV31Ctag-L1, pTO-T7-HPV31Ctaa-L1 and the pTO-T7-HPV31Ctga- of 1 μ L are taken respectively
L1（0.15mg/ml）The competence escherichia coli ER2566 for converting 40 μ L and being prepared with Calcium Chloride Method（It is biological real purchased from New England
Yan Shi companies）, coated containing kanamycin（Final concentration 25mg/mL, similarly hereinafter）Solid LB media（LB culture medium into
Point：10g/L peptones, 5g/L yeast powders, 10g/L Sodium Chloride, similarly hereinafter）, and 37 DEG C of quiescent culture 10-12 hours are clear to single bacterium colony
It is clear distinguishable.Picking single bacterium colony is to LB liquid medium containing 4mL respectively（Containing kanamycin）Test tube, under 37 DEG C 220 revs/min
Shaken cultivation 10 hours, therefrom takes 1mL bacterium solutions and preserves in -70 DEG C.
The expression and purification of the HPV31L1 albumen of the gene code of 2. different termination codoies of embodiment
The expression and purification of HPV31L1 albumen is described by taking HPV31Ctag-L1 as an example herein.
The great expression of HPV31Ctag-L1 albumen
The Escherichia coli bacteria liquid for carrying recombiant plasmid pTO-T7-HPV31Ctag-L1 is taken out from -70 DEG C, is inoculated with into 50ml
In LB fluid mediums containing kanamycin, in 200rpm, about 8 hours at 37 DEG C, are cultivated；Then transfer and contain into 10 bottles of 500ml
In the LB culture medium of kanamycin（Per bottle of access 5ml bacterium solution）, in 200rpm, overnight incubation at 37 DEG C, as seed liquor.
The 50L fermentation tanks produced using Shanghai Bao Xing biotech firms carry out large-scale culture.Correction fermentation tank PH electrodes, will
30L LB culture medium loads fermentation tank, 121 DEG C of sterilizings 30min in situ；Correction dissolved oxygen electrode, being zero before not ventilating after sterilizing
Point, as 100% during initial mixing speed 100rpm before not being inoculated with after ventilating during fermenting.
Feed supplement prepares：Prepare 30% peptone and yeast extract mixture（20g peptones, 10g yeast extracts are molten to 100ml）,
50% glucose (50g is molten to 100ml), 121 DEG C of sterilizing 20min.
Next day accesses 10 bottles of seed liquor common 5L in fermentation tank, 37 DEG C of design temperature, pH value 7.0, adjusts stirring speed manually
Degree and ventilation, maintenance dissolved oxygen is more than 40%.
Flow feeding：By 50% glucose and 30% peptone and yeast extract mixture compare 2 by Solute mass：1 ratio
Example mixing.
Flow acceleration is as follows：First hour：5%；Second hour：10%；3rd hour：20%；4th hour：40%；5th
Hour and later 60%（With 25mL/min as 100%）.
When bacterial concentration reaches OD600For 10 or so when, cultivation temperature is down to into 25 DEG C, 4g IPTG inducing culture 4 is added
Hour.Final concentration of about 60（OD600）, lower tank is collected by centrifugation thalline.Acquisition expresses the thalline of HPV31Ctag-L1 albumen,
Weigh about 2.5kg.Same method prepares respectively and expresses the thalline of HPV31Ctaa-L1 albumen and express HPV31Ctga-L1 eggs
White thalline.
Weighed by the ratio of 1g thalline correspondence 10mL lysates (20mM Tris buffer, pH7.2,300mM NaCl) respectively
Outstanding thalline.APV homogenizers (An Invensys Group products) are adopted with 600bar pressure breakings thalline 5 times.With 13500rpm
(30000g) bacterial cell disruption liquid 15min is centrifuged, leaves and takes supernatant（That is, bacteria break supernatant）.
The cation exchange chromatography of HPV31Ctag-L1
Dithiothreitol, DTT is added toward the bacterial cell disruption supernatant containing HPV31Ctag-L1 albumen（DTT）So as to final concentration
Reach 20mmol/L.20min is centrifuged with 15000rpm (40000g) using Beckman J25 high speed centrifuges, supernatant is harvested.
The sample for being obtained（That is, the molten rear supernatant of weight）For carrying out cation exchange chromatography：
Instrument system：GE Healthcare companies（Former Amershan Pharmacia companies）The AKTA of production
Explorer100 type preparative liquid chromatography systems.
Chromatography media：SP Sepharose4Fast Flow（GE Healthcare companies）.
Column volume：5.5cm×20cm.
Buffer：20mM phosphate buffer pH8.0,20mM DTT
20mM phosphate buffer pH8.0,20mM DTT, 2M NaCl.
Flow velocity：25mL/min
Detector wavelength：280nm.
Sample is the HPV31Ctag- of 0.22 μm of aperture membrane filtration of Jing the, purity about 10% obtained in above-mentioned steps
L1 protein solutions.
Elution program is：500mM NaCl eluting foreign proteins, 1000mM NaCl eluting destination proteins collect 1000mM
NaCl elutriated fractions.
The hydrophobic exchange purification of HPV31Ctag-L1
Instrument system：GE Healthcare companies（Former Amershan Pharmacia companies）The AKTA of production
Explorer100 type preparative liquid chromatography systems.
Chromatography media：Butyl Sepharose4Fast Flow（GE Healthcare companies）
Column volume：5.5cm×20cm
Buffer：20mM phosphate buffer pH8.0,20mM DTT
20mM phosphate buffer pH8.0,20mM DTT, 2M NaCl.
Flow velocity：20mL/min.
Detector wavelength：280nm.
Sample is：The 1000mM NaCl elutriated fractions that previous step is obtained.
Elution program is：300mM NaCl eluting destination proteins, collect elutriated fraction during 300mM NaCl concentrations.
The CHT II of HPV31Ctag-L1（Hydroxylapatite chromatography）Purification
Instrument system：GE Healthcare companies（Former Amershan Pharmacia companies）The AKTA of production
Explorer100 type preparative liquid chromatography systems.
Chromatography media：CHT- II (being purchased from Bio-RAD)
Column volume：5.5cm×20cm
Buffer：20mM phosphate buffer pH8.0,20mM DTT
20mM phosphate buffer pH8.0,20mM DTT, 2M NaCl.
Flow velocity：20mL/min.
Detector wavelength：280nm.
Sample is：The 300mM NaCl elutriated fractions that previous step is obtained.
Elution program is：500mM NaCl eluting foreign proteins, 1000mM NaCl eluting destination proteins collect 1000mM
Elutriated fraction during NaCl concentration, so as to obtain HPV31tag-L1 albumen after purification.By what is obtained in each purification step
HPV31tag-L1 protein samples carry out SDS-PAGE analyses, and as a result as shown in figure 1, as a result showing, HPV31Ctag-L1 albumen exists
After chromatographic step by 3 steps, purity has brought up to about 95% from about 10% before（Referring to swimming lane 1 and 4）.Using same
Method, purification obtains HPV31taa-L1 albumen and HPV31tga-L1 albumen.The HPV31tag- that will be obtained in each purification step
L1 albumen, HPV31taa-L1 albumen and HPV31tga-L1 albumen carry out SDS-PAGE analyses, as a result as shown in Fig. 2 result table
Bright, after by the chromatographic step of 3 steps, purity has brought up to about 95% from about 10% before to HPV31Ctag-L1 albumen
(Fig. 2 swimming lanes；And HPV31Ctaa-L1 and HPV31Ctga-L1 albumen Jing same step is after purification, purity can only bring up to
85%.Above the purpose band of about 55kD, the foreign protein band for having a 60kD have impact on the purity of albumen, account for total protein
The 10% of amount.See Fig. 2 swimming lane 1-3 and 4-6.
The identification of embodiment 3.HPV31taa-L1 albumen and HPV31tga-L1 albumen and analysis
The protein immunoblotting detection of HPV31Ctaa-L1
The HPV31taa-L1 albumen that purification is obtained is carried out into electrophoresis, after electrophoresis terminates, using HPV31L1 specific antibody 8G6
And 11D2 carries out Western detections respectively, as a result sees Fig. 3.As a result show, the foreign protein of the purpose band and 60kD of 55kD
Band can be reacted with HPV31L1 specific antibodies 8G6 and 11D2, it was demonstrated that the band contains HPV31L1 albumen.
The mass spectral analyses of the 60kD protein bands of HPV31Ctaa-L1 and HPV31Ctga-L1
HPV31taa-L1 albumen and HPV31Ctga-L1 albumen are carried out into electrophoresis respectively, after electrophoresis terminates, using coomassie
Light blue is dyeed, and the foreign protein band of the 60kD above the purpose band of 55kD is cut.Albumen blob of viscose is with 40 μ L destaining solution（30%
ACN, 50mmol/L ammonium acetate, pH7.0）Decolourize twice, each 30min, and it is interrupted vibration 3～5 times, abandon after brief centrifugation
Clearly.Then SDS and salt ion are removed with ethanol-chloroform, adds 40 μ LACN to be dehydrated 3～4min, abandon supernatant.Blown with nitrogen
It is dry（About 20min）, then 10 μ L trypsin working solutions are added in dried blob of viscose（50ng/μL）, pre- enzymolysis 1h under room temperature,
Trypsin is made to fully penetrate in blob of viscose.It is subsequently adding 40 μ L enzymolysis buffer（0.5mmol/LCaCl2,50mmol/L acetic acid
Ammonium, pH7.0）, 16～20h of vibration enzymolysis in 37 DEG C of water-baths.Enzymolysis solution is centrifuged into 20s in 10000 × g, supernatant, blob of viscose is collected
Respectively with 40 μ L extract I（0.1%TFA）, extract II（30%ACN, 0.1%TFA）With extract III（60%ACN, 0.1%
TFA）Extract successively, respectively extracting 1 time of every kind of extract vibrates 30min during extracting under 30 DEG C of water-baths.By supernatant after extracting every time
10000 × g of liquid is centrifuged 20s, collects supernatant and is dried up with nitrogen.Dried peptide fragment is redissolved to enter in Matrix buffer
Row mass spectral analyses.
The MALDI-TOF-TOF tandem mass spectrometers for using（Waters, US）Peptide fragment to digesting is examined respectively
Survey.The first mass spectrometric information of each target spot is gathered using reflective-mode（MS）, laser intensity is 4000, quality of scanning scope 800
～4000Da, after the completion of first mass spectrometric scanning, choosing 10 signal intensity highest parent ions carries out second mass analysis, accelerates
Voltage 2kV, using Collision-induced dissociation parent ion, obtains the fragment ion dactylogram of each parent ion.By one-level, second mass analysis
The data of acquisition import GPS software, are analyzed using Mascot algorithm synthesis, search for matching in NCBI Protein Data Banks
Protein.Search condition parameter：Enzymolysis type includes Trypsin and peptide mapping fingerprinting error, and modified types include phosphoric acid
Change modification and alkylation is modified；Search Results are with confidence level>95% is identification Success criteria.According to spectrogram and Mascot scores ratio
Compared with qualification result and peptide fragment coverage rate.The 60kD protein bands of the HPV31Ctaa-L1 that search is obtained and HPV31Ctga-L1 are identified
As a result such as Fig. 4 and Fig. 5.As a result show, the 60kD protein bands of HPV31Ctaa-L1 and HPV31Ctga-L1 contain HPV31L1
Albumen.The result of comprehensive protein immunoblot and Mass Spectrometric Identification, the 60kD albumen ones of HPV31Ctaa-L1 and HPV31Ctga-L1
Band is not exclusively to introduce the albumen of carrier sequence by termination when translating.HPV31L1 with TAG as termination codon as can be seen here
Sequence is expressed, and compared with sequence of the termination codon for TAA or TGA, greatly improves the efficiency of translation termination, it is to avoid mistake
The generation of the HPV31L1 albumen for terminating by mistake, reduces the difficulty of purifying process, and in making stock solution, purity of protein is brought up to from 85%
95%。
The assembling of the virus-like particle of the HPV31L1 of the gene code of 4. different termination codoies of embodiment
Instrument system is the CENTRASETTE5 tangential flow systems of PALL productions；Film bag molecular cut off is 30kDa；Sample
HPV31tag-L1 albumen obtained by embodiment 2, HPV31taa-L1 albumen and HPV31tga-L1 albumen.
The renaturation of sample：With renaturation buffer（50mM PB（Sodium phosphate buffer）PH6.0,2mM CaCl2, 2mM
MgCl2, 0.5M NaCl, 0.003%Tween-80）Sample buffer is fully exchanged, and volume is exchanged for the 10 of sample initial volume
More than times.The operating pressure of tangential flow apparatus is 0.5psi, and slipstream speed is 10mL/min.Exchange in renaturation buffer
Afterwards, use storage buffer solution（20mM PB（Sodium phosphate buffer）PH6.5,0.5M NaCl）Swap, exchange volume is sample
More than 4 times of volume.The operating pressure of tangential flow apparatus is 0.5psi, and slipstream speed is 25mL/min.After exchange is finished, use
PALL0.20 μm of filter sterility filtered sample, obtains HPV31tag-L1 virus-like particles, HPV31taa-L1 virus-like particles and
HPV31tga-L1 virus-like particles, are placed on 4 DEG C and save backup.
Embodiment 5：The morphologic detection of the HPV31L1 virus-like particles of the gene code of different termination codoies
The transmission electron microscope observing of the HPV31L1 virus-like particles of the gene code of different termination codoies
The instrument for using is the 100kV transmission electron microscopes of NEC company's production, and amplification is 100,000 times.Will be real
4 gained HPV31tag-L1 virus-like particles of example are applied, HPV31taa-L1 virus-like particles and HPV31tga-L1 virus-like particles are used
2% phosphotungstic acid pH7.0 negative staining, is fixed on the copper mesh of spray charcoal, is observed.Electronic Speculum result is shown in Fig. 6-Fig. 8.As a result show, wherein
HPV31tag-L1 virus-like particles visible a large amount of radiuses under Electronic Speculum are the virus-like particle of 25nm or so, uniform in size, are presented
For hollow form；And virus-like particle of the visible part radius for 25nm or so in the visual field, but HPV31taa-L1 virus-like particles
Under Electronic Speculum, visible part radius is the virus-like particle of 25nm or so with HPV31tga-L1 virus-like particles, and size is uneven, disease
Malicious sample grain shape is also relatively irregular, and surrounding has a large amount of unassembled albumen.As can be seen here, HPV31tag-L1 is viral
The form of sample granule is better than HPV31taa-L1 virus-like particles and HPV31tga-L1 virus-like particles with packaging efficiency.
The dynamic light scattering detection of the HPV31L1 virus-like particles of the gene code of different termination codoies
The instrument for using is the DynaPro MS/X type dynamic light scatterings of Protein Solutions companies of U.S. production
（Containing temperature controller）, the algorithm for using is Regulation algorithms.Sample is 4 gained HPV31tag-L1 virus-likes of embodiment
Granule, HPV31taa-L1 virus-like particles and HPV31tga-L1 virus-like particles.Sample is carried out Jing after 0.22 μm of membrane filtration
Measurement.Measurement result is shown in Fig. 9-Figure 11.As a result show, the hydrated molecule kinetics radius of HPV31tag-L1 virus-like particles are
28.49nm, assembling percentage ratio are 98.5%；And HPV31taa-L1 virus-like particles and HPV31tga-L1 virus-like particles are measured
Hydrated molecule kinetics radius in 55nm or so, and there is less or larger impurity composition, impurity composition is accounted for
10%。
The sieve chromatography analysis of the HPV31L1 virus-like particles of the gene code of different termination codoies
Terminate close using the 1120Compact LC highly effective liquid phase chromatographic systems chromatographic analysises of Agilent company of the U.S. are different
The HPV31L1 virus-like particles of the gene code of numeral, the analytical column for using are TSK Gel PW5000xl7.8x300mm.With 2
The absorption value of detector is returned by the absorption value at the PBS pre-balances chromatographic column to 280nm of times column volume without significantly change
Zero.By automatic sampler sample introduction analysis result.As a result as shown in figure 12, as a result show, HPV31Ctag-L1 virus-like particles
Peak type is the most symmetrical, without other components, illustrates that its component is homogeneous；HPV31Ctaa-L1 virus-like particles have 18min's or so
The unassembled component into virus-like particle, accounts for 10%；And HPV31Ctga-L1 virus-like particles not only have small component to also have big group
Point.
The result of integrated embodiment 5, it is known that HPV31Ctag-L1 virus-like particle assemblings rate is high（Higher than 95%）, acquisition
Virus-like particle is homogeneous, all consistent with wild type HPV31 protein coats form and size.And HPV31Ctaa-L1 virus-like particles
Then assembling rate is relatively low with HPV31Ctga-L1 virus-like particles（Less than 90%）, the virus-like particle of acquisition also form heterogeneity.Cause
This using the gene order of HPV31Ctag-L1 carry out protein expression can make HPV31L1 protein groups dress virus-like particle efficiency from
90% brings up to 98%.
The measure of embodiment 6.HPV31tag-L1 protein immunogenic
Foundation in HPV31 pseudoviruss with cell model
As HPV is difficult to be cultivated in vitro, and HPV host specificities are strong, it is difficult to numerous on the host beyond people
Grow, lack suitable animal model, therefore, in order to be able to the immune protective to HPV vaccines carries out rapid evaluation, need to set up
It is effectively external to neutralize experimental model.
Pseudoviruss（pseudovirions）Infection in Vitro model:Can the non-specific spy for packing nucleic acid using HPV VLP
Property, by L1 the and L2 albumen for expressing HPV in the cell, imported by the intracellular episome viral DNA of parcel or external source
Reporter plasmid, constitutes HPV pseudoviruss (Yeager, M.D, Aste-Amezaga, M.et al (2000) Virology (278)
570-7).Concrete grammar includes expression of recombinant virus systems approach and many plasmid co-transfection methods.The present embodiment is exemplary using many
Plasmid co-transfection method.
The construction method of HPV pseudoviruss is as follows：
Coding HPV31L1 albumen (NCBI data are carried (with CsCl density gradient centrifugation methods difference plasmid purification p31L1h
Storehouse, P17388.1) nucleotide sequence pAAV carriers), plasmid p31L2h (carry coding HPV31L2 albumen (NCBI data
Storehouse, P17389.1) nucleotide sequence pAAV carriers) and the plasmid pN31-EGFP with green fluorescence protein gene
（PN31-EGFP and above-mentioned pAAV carriers are given by John professors T.Schiller of NIH）.Using CsCl density gradients
Centrifugation come plasmid purification method be it is known in the art that referring to《Molecular cloning：The third edition》.
Using calcium phosphate transfection method, with each 40 μ g cotransfections of p31L1h, p31L2h, pN31-EGFP after purification cultivate in
293FT cells in 10cm Tissue Culture Dishs（Invitrogen）.Calcium phosphate transfection method be it is known in the art that referring to《Molecule
Clone：The third edition》.In short, p31L1h, p31L2h, pN31-EGFP each 40 μ g to be added the HEPES solution of 1mL（Per 50mL
Deionized water contains the 1M Hepes125 μ L of pH=7.3,4 DEG C of storages）With the 0.5mol/L CaCl of 1mL2The mixing of solution is molten
In liquid, mix, be then added dropwise over 2mL2 × HeBS solution（0.28M NaCl (16.36g), 0.05M HEPES (11.9g),
1.5mMNa2HPO4(0.213g) 1000mL deionized waters, pH=6.96, -70 DEG C of storages, are dissolved in）In, stand under room temperature
1min；Then add culture to have in the 10cm Tissue Culture Dishs of 293FT cells mixed liquor, cultivate 6hr；Then discard former culture
Liquid, the complete culture solution for adding 10mL fresh（Invitrogen companies）.After transfection 48hr, culture medium is discarded, it is thin with PBS
Born of the same parents 2 times；Then cell is scraped into collection cell, carries out cell counting, and per 108Individual cell 1mL lysates（0.25%
Brij58,9.5mM MgCl2）It is resuspended.After cracking, 10min is centrifuged with 5000g, collects supernatant, add 5M NaCl（Final concentration
For 850mM）, so as to obtain cape horn fever venom, after being packed as aliquot, it is placed in -20 DEG C of preservations.
The measure of antibody dilution factor
By 293FT cells（Invitrogen）It is laid in 96 porocyte culture plates（1.5×104/ hole）.Enter after 5hr as follows
Row neutralization experiment：By blood serum sample to be measured（Containing test antibodies）Continuous doubling dilution, Ran Houqu are carried out with 10%DMEM respectively
The cape horn fever venom produced above that 50 μ L each diluted sample is diluted in 10%DMEM with 50 μ L respectively mixes（moi=
0.1）；After 1h is incubated at 4 DEG C, by mixture be separately added into it is pre- be covered with 96 porocyte culture plates of 293FT cells, and 37
DEG C culture 72h；Then first pass through Fluirescence observation and determine the general antibody titer of each sample, then use flow cytometer（EPICS XL,
Beckman Coulter companies of the U.S.）The infection rate of each hole cell is detected, the accurate antibody titer of serum is calculated.Infection rate is
Cell quantity percentage rate of the cell sample to be measured in hot spot deducts number of the compared with control cells sample being uninfected by hot spot
Amount percentage rate.
Infection suppression ratio=（1 ﹣ adds the infection rate in the hole of infection rate/the do not add serum in the hole of serum）×100%.
Median effective dose (50%effective dose, ED50), here represent half infection suppression ratio, i.e., 50% infection
Suppression ratio, in this as the unit of antibody dilution factor.
The definition of antibody dilution factor is：Reach higher than 50% infection suppression ratio（ED50）Maximum dilution multiple, for example certain
It is higher than ED afterwards that serum antibody dilutes 5120 times50, and 10240 times are then less than ED50, then its antibody dilution factor is 5120ED50.Jing
The antibody for remaining to reach after 20 times of dilutions more than 50% infection suppression ratio is considered with neutralising capacity,<20ED50Then it is considered as not
With neutralising capacity, 10ED is designated as50。
HPV31tag-L1 virus-like particles are used for the evaluation of the immune protective of immune animal
The immune protective of the HPV31tag-L1 virus-like particles of the present invention using rat evaluation.Immunity with animal is
4-5 week old SPF levels BALB/c mouse 5.HPV31tag-L1 virus-like particles are prepared according to embodiment 1-4 methods described.Will
The granule is diluted to 0.1mg/ml, is subsequently adding isopyknic complete Freund's adjuvant（For initial immunity）Or it is isopyknic complete
Full Freund adjuvant（For booster immunization）, mix homogeneously.Immune programme for children is：Initial immunity when 0 week；Strengthen when 2,4 and 6 weeks.Exempt from
Epidemic disease mode is intramuscular injection, and initial immunity dosage is 10 μ g/, and booster immunization dosage is 10 μ g/.
After initial immunity, peripheric venous blood was extracted per 2 weeks, serum is separated.Then mice serum is detected according to said method
In for HPV31 pseudovirions NAT.Testing result is as shown in figure 13.As a result show, according to embodiment 1-4
The HPV31tag-L1 virus-like particles that methods described is obtained have good immunogenicity, can be in mice Immune inducing in vivo 105More than
The neutralizing antibody for HPV31 of titre, and the sustainable effective vaccine that can be used as preventing HPV31 infection.Except using Freund
Outside adjuvant, the vaccine can also use other adjuvants well known in the art, such as aluminium hydroxide or Aluminium phosphate adjuvant.
The immune protective of the HPV31tag-L1 virus-like particle of the present invention is have rated using rabbit also.Animal is used in immunity
For 6～8 week old regular grade female rabbit 4（Purchased from Guangxi province disease prevention and control center）.By prepared by embodiment 1-4
HPV31tag-L1 virus-like particles are diluted to 1.0mg/ml, are subsequently adding isopyknic complete Freund's adjuvant（For exempting from for the first time
Epidemic disease）Or isopyknic incomplete Freund's adjuvant（For booster immunization）, mix homogeneously.Immune programme for children is：Initial immunity when 0 week；
Strengthen when 4,8 and 12 weeks.Immunization wayses are intramuscular injection, and initial immunity dosage is 1.0mg/, and booster immunization dosage is
1.0mg/ only.
After initial immunity, peripheric venous blood was extracted per 2 weeks, serum is separated.Then rabbit serum is detected according to said method
In for HPV31tag-L1 virus-like particles NAT.Testing result is as shown in figure 14.As a result show, according to reality
Apply a HPV31tag-L1 virus-like particle for 1-4 methods describeds acquisition and there is good immunogenicity, can be in rabbit Immune inducing in vivo
The neutralizing antibody for HPV31 of high titre, can be used as preventing the effective vaccine of HPV31 infection.In addition to using Freund adjuvant,
The vaccine can also use other adjuvants well known in the art, such as aluminium hydroxide or Aluminium phosphate adjuvant.
Result above shows that the HPV31tag-L1 virus-like particles obtained by the method for the present invention have good exempting from
Epidemic focus, can induced high titers in animal body neutralizing antibody, so as to can be used as preventing the vaccine of HPV infection.
Embodiment 7：The termination codon of the gene order of coding HPV31L1 albumen compares analysis
Using Mega4.0 softwares to 32 HPV31L1 gene orders in existing NCBI nucleic acid databases
（Goldsborough,M.D.,DiSilvestre,D.,Temple,G.F.,et al.,Virology,1989.171(1):
p.306-11.;Icenogle,J.P.,Clancy,K.A.,and Lin,S.Y.,Virology,1995.214(2):p.664-
9.;Bousarghin,L.,Touze,A.,Sizaret,P.Y.,et al.,J Virol,2003.77(6):p.3846-
50.Fleury,M.J.,Touze,A.,de Sanjose,S.,et al.,Clin Vaccine Immunol,2008.15(1):
p.172-5.;Chen,Z.,Schiffman,M.,Herrero,R.,et al.,PLoS One,2011.6(5):p.e20183.;
Dubin,G.,Innis,B.,Slaoui,M.M.and Wettendorff,M.A.Patent:WO2006114273-A502-
NOV-2006;Jansen,K.U.,Schultz,L.D.,Neeper,M.P.and Markus,H.Z.Patent:
KR1020057017936-A323-SEP-2005,JP2006523099-A112-OCT-2006;）, including 25 wild types
Sequence and 7 artificial sequences, compare, wherein the comparison result that each sequence 3 ' is held is as shown in figure 15.The result shows,
The gene order of the HPV31L1 of wild type HPV31L1 gene orders and existing synthetic is using TAA as termination codon
Son, and report is there is no using TAG as the sequence of termination codon.
Although the specific embodiment of the present invention has obtained detailed description, it will be appreciated by those skilled in the art that：Root
According to disclosed all teachings, various modifications and changes, and these changes can be carried out to details in the guarantor of the present invention
Within the scope of shield.The four corner of the present invention is given by claims and its any equivalent.
Claims (8)
1. the detached nucleic acid of 31 type L1 albumen of human papillomavirus is encoded, it is characterised in that the detached nucleic acid with TAG is
Termination codon, the nucleotide sequence such as SEQ ID NO of the nucleic acid:Shown in 1.
2. the carrier of the detached nucleic acid of claim 1 is included.
3. the host cell of the carrier of claim 2 is included, and which is Bacillus coli cells.
4. a kind of compositionss, which includes the detached nucleic acid of claim 1, or the carrier of claim 2, or claim 3
Host cell.
5. it is used for preventing HPV infection or the vaccine by the caused disease of HPV infection institute, which includes the detached core of claim 1
Acid, or the carrier of claim 2, or the host cell of claim 3, optionally also include pharmaceutically acceptable carrier and/or
Excipient.
6. the method for preparing HPV31L1 albumen, methods described include step：
A) expression in escherichia coli encode HPV31L1 albumen detached nucleic acid, the coding HPV31L1 albumen it is detached
The sequence of nucleic acid such as SEQ ID NO:Shown in 1；
B) will expression HPV31L1 albumen escherichia coli salinity for 100mM-600mM solution in crush, it is isolated on
Clear liquid, adds reducing agent DTT or 2 mercapto ethanol, and its consumption is 10mM-100mM；
C) the HPV31L1 albumen of acquisition is carried out into purification by chromatography.
7. the method for claim 6, which also includes step：
The HPV31L1 albumen for preparing is removed into reducing agent.
8. a kind of method for preparing vaccine, which includes：
A) in expression in escherichia coli such as SEQ ID NO:The detached nucleic acid of the coding HPV31L1 albumen shown in 1；
B) will expression HPV31L1 albumen escherichia coli salinity for 100mM-600mM solution in crush, it is isolated on
Clear liquid, adds reducing agent DTT or 2 mercapto ethanol, and its consumption is 10mM-100mM；
C) the HPV31L1 albumen of acquisition is carried out into purification by chromatography；
D) the HPV31L1 albumen for preparing is removed into reducing agent；
E) the HPV31L1 albumen for preparing is formed into virus-like particle and is mixed with pharmaceutically acceptable carrier and/or excipient, appointed
Selection of land also mixes one or more selected from HPV6, the virus-like particle of 11,16,18,45,33,52 and 58 HPV types.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310217596.6A CN104212818B (en) | 2013-06-04 | 2013-06-04 | Optimized gene sequence of human papillomavirus 31 type L1 protein |
| HK15105725.4A HK1207879A1 (en) | 2013-06-04 | 2015-06-16 | An optimized gene sequence encoding for the l1 protein of human papillomavirus type 31 31 l1 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310217596.6A CN104212818B (en) | 2013-06-04 | 2013-06-04 | Optimized gene sequence of human papillomavirus 31 type L1 protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104212818A CN104212818A (en) | 2014-12-17 |
| CN104212818B true CN104212818B (en) | 2017-04-12 |
Family
ID=52094726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310217596.6A Active CN104212818B (en) | 2013-06-04 | 2013-06-04 | Optimized gene sequence of human papillomavirus 31 type L1 protein |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN104212818B (en) |
| HK (1) | HK1207879A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106701797B (en) * | 2015-08-12 | 2021-06-15 | 北京康乐卫士生物技术股份有限公司 | 31 type recombinant human papilloma virus-like particle and preparation method thereof |
| CN106893730B (en) * | 2015-12-18 | 2021-06-11 | 上海泽润生物科技有限公司 | Recombinant human papilloma protein expression |
| CN108201623A (en) * | 2016-12-19 | 2018-06-26 | 无锡鑫连鑫生物医药科技有限公司 | Human papilloma virus recombination tetravalent vaccine, preparation method and its application |
| CN114127097A (en) * | 2019-07-19 | 2022-03-01 | 神州细胞工程有限公司 | Chimeric human papilloma virus 56 type L1 protein |
| WO2021013062A1 (en) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | Chimeric human papillomavirus type 31 l1 protein |
| CN112920267B (en) * | 2021-03-09 | 2021-08-13 | 北京康乐卫士生物技术股份有限公司 | Monoclonal neutralizing antibody against human papillomavirus 31 and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101914139B (en) * | 2010-07-16 | 2012-11-21 | 四川大学 | Human papilloma virus (HPV) capsid protein L1 polypeptide and preparation and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008538922A (en) * | 2005-04-28 | 2008-11-13 | メルク エンド カムパニー インコーポレーテッド | Fluorescence multiplex HPV PCR assay |
-
2013
- 2013-06-04 CN CN201310217596.6A patent/CN104212818B/en active Active
-
2015
- 2015-06-16 HK HK15105725.4A patent/HK1207879A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101914139B (en) * | 2010-07-16 | 2012-11-21 | 四川大学 | Human papilloma virus (HPV) capsid protein L1 polypeptide and preparation and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| Codon pairs in the genome of Escherichia coli;Svetlana等;《BIOINFORMATICS》;20031231;第19卷(第8期);第987-998页，尤其是第993页右边栏第3段 * |
| Human Papillomavirus Types 16, 31, and 58 Use Different Endocytosis Pathways To Enter Cells;Latifa等;《JOURNAL OF VIROLOGY》;20030331;第77卷(第6期);第3846-3850页及后附页，尤其是第1页右边栏第3段，后附页倒数第1、4-5页、 * |
| 几种模式生物密码对的偏好模式分析;王芳平等;《中国医学物理学杂》;20111130;第28卷(第6期);第3059-3063页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104212818A (en) | 2014-12-17 |
| HK1207879A1 (en) | 2016-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104212818B (en) | Optimized gene sequence of human papillomavirus 31 type L1 protein | |
| CN101293918B (en) | Shorten human papilloma virus 16 type L1 protein | |
| CN112076315A (en) | Nano antigen particle fused with new coronavirus S protein and ferritin subunit, new coronavirus vaccine, and preparation method and application thereof | |
| CN102229660B (en) | Truncated human papillomavirus 33 type L1 protein | |
| CN101343314B (en) | The Human Papillomavirus Type 11 L1 albumen of brachymemma | |
| EP2589604B1 (en) | Truncated l1 protein of human papillomavirus type 52 | |
| US9745351B2 (en) | Truncated L1 protein of human papillomavirus type 6 | |
| CN101153280A (en) | Method for purifying human papilloma virus advanced protein from prokaryote | |
| JP2019502404A (en) | Mutation of human papillomavirus type 11 L1 protein | |
| US9738691B2 (en) | Truncated L1 protein of human papillomavirus type 58 | |
| CN101570571B (en) | Truncated human papilloma virus 18 type L1 protein | |
| CN103936840A (en) | Recombinant human papilloma virus type 33 L1 protein and its purpose | |
| WO2016026401A1 (en) | Method for enhancing hpv epitope peptide immunogenicity, viroid particle, particle preparation method and application | |
| CN106399329A (en) | Virus-like particle of recombined human papillomavirus 33 and preparation method of virus-like particle | |
| CN104211782B (en) | The type L1 albumen of HPV 45 of truncation | |
| CN114127092B (en) | Human papillomavirus multivalent immunogenic compositions | |
| CN104045696A (en) | Recombinant human papilloma virus 16L1 protein and its use | |
| CN114127096B (en) | Chimeric human papillomavirus 31-type L1 protein | |
| CN114127127B (en) | Chimeric human papillomavirus 35 type L1 protein | |
| CN104045695B (en) | HPV 18 L1 albumen of recombination and application thereof | |
| CN106701796A (en) | Recombinant human papilloma virus 52 virus-like particle and preparation method thereof | |
| JP2021535077A (en) | Mutant of L1 protein of human papillomavirus type 18 | |
| CN106701798A (en) | Type-45 recombinant human papillomavirus virus-like particles and preparation method thereof | |
| CN106893730A (en) | Restructuring human papilloma protein expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1207879 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1207879 Country of ref document: HK |